Investors who purchased the Company's securities between
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Myriad failed to gather evidence to demonstrate benefits of GeneSight testing. The FDA requested changes to GeneSight and questioned its value. The Company engaged in ongoing discussions with the FDA about these changes. Myriad’s acquisition of
Join the case to recover your losses.
This press release may be considered